The use of azelastine nasal spray improves the compliance of patients with allergic rhinitis

Article Sidebar

PDF (Język Polski)


Published: Jun 15, 2013
Keywords:
allergy, allergic rhinitis, therapy, azalastine

Main Article Content

Piotr Rapiejko
1. Klinika Otolaryngologii, Wojskowy Instytut Medyczny w Warszawie. 2. Zakład Profilaktyki Zagrożeń Środowiskowych i Alergologii, Warszawski Uniwersytet Medyczny

Abstract

The latest therapeutic recommendations suggest the use of nasal steroids instead of antihistaminics in treatment of allergic rhinitis. High effectiveness of nasal steroids in removing allergic inflammation symptoms is unquestionable. Though the beginning of action is observed in few hours following application and full clinical effect in few days of regular use. From the practical point of view the application of antihistaminic agents (nasal and oral) parallel to nasal steroids seems to be appropriate. It is especially important in patients with intensified allergic symptoms, accompanied with oedema of nasal mucosa, leading to nasal blockade. The application of nasal steroids as the only agent in patients with intensified allergic symptoms do not guarantee immediate relief and may lead to poor patient’s compliance. The aim of therapy in allergic rhinitis is removing local symptoms by local blocking of allergic reaction as well as complex treatment, together with elements of prophylaxis. The application of nasal antihistaminics (in Poland the preparation with azelastine is registered) bring relief in a few minutes due to quick beginning of action.

Downloads

Download data is not yet available.

Article Details

How to Cite
Rapiejko , P. (2013). The use of azelastine nasal spray improves the compliance of patients with allergic rhinitis. Alergoprofil, 9(2), 5-10. Retrieved from https://journalsmededu.pl/index.php/alergoprofil/article/view/761
Issue
Vol 9 No 2 (2013)
Section
Article

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Samoliński B., Sybilski A.J., Raciborski F., Tomaszewska A., Samel-Kowalik P., Walkiewicz A., Lusawa A., Borowicz J., Gutowska-Ślesik J., Trzpil L., Marszałkowska J., Jakubik N., Krzych E., Komorowski J., Lipiec A., Gotlib T., Samolińska-Zawisza U., Hałat Z.: Prevalence of rhinitis in Polish population according to the ECAP (Epidemiology of Allergic Disorders in Poland) study. Otolaryngol. Pol. 2009, 63(4): 324-30.
2. Lipiec A., Komorowski J., Sybilski A., Samoliński B.: Epidemiologia chorób alergicznych. W: Alergia, choroby alergiczne, astma. Tom 1. Fal A. (red.). Medycyna Praktyczna, Kraków 2010: 112-126.
3. Bachert C., van Cauwenberge P., Khaltaev N.; World Health Organization: Allergic rhinitis and its impact on asthma. Allergy 2002, 57(9): 841-55.
4. Brożek J.L., Bousquet J., Baena-Cagnani C.E. et al.: Allergic rhinitis and its impact on asthma (ARIA) guidelines: 2010 revision. J. Allergy Clin. Immunol. 2010, 126: 466-476.
5. Samoliński B., Rapiejko P.: Odpowiedź wczesna po donosowej próbie prowokacyjnej z alergenem. Post. Dermatol. Alergol. 2010, 27(3): 170-172.
6. Polskie Standardy Leczenia Nieżytów Nosa. Alergologia Polska 2013, S1.
7. Samoliński B., Rapiejko P.: Odpowiedź późna po donosowej próbie prowokacyjnej z alergenem. Post. Dermatol. Alergol. 2010, 27(3): 173-176.
8. Hellings P.W., Fokkens W.J., Akdis C., Bachert C., Cingi C., Dietz de Loos D., Gevaert P., Hox V., Kalogjera L., Lund V., Mullol J., Papadopoulos N.G., Passalacqua G., Rondo´n C., Scadding G., Timmermans M., Toskala E., Zhang N., Bousquet J.: Uncontrolled allergic rhinitis and chronic rhinosinusitis: where do we stand today? Allergy 2013, 68(1): 1-7.
9. Rapiejko P.: Alergiczne zapalenie błony śluzowej nosa – jak leczyć nasilenie dolegliwości? Alergoprofil 2010, 6(4): 4-7.
10. Rapiejko P.: Donosowe glikokortykosteroidy w leczeniu chorób nosa i zatok przynosowych. Terapia 2012, 12: 61-66.
11. Carr W.W., Bernstein J., Lieberman P., Meltzer E., Bachert C., Price D., Munzel U., Bousquet J.: A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J. Allergy Clin. Immunol. 2012, 129: 1282-1289.
12. Carr W.W., Ratner P., Munzel U., Murray R., Price D., Canonica G.W., Mullol J., Virchow J.C., Lieberman P., Meltzer E., Bachert C.: Comparison of intranasal azelastine to intranasal fluticasone propionate for symptoms control in moderate-to-severe seasonal allergic rhinitis. Allergy Astma Proc. 2012, 33: 450-458.
13. Hampler F.C., Rather P.H., Van Baval J. et al.: Double blind, placebo controlled study if AZE and fluticasone in a single nasal spray delivery device. Ann. Allergy Asthma Immunol. 2010, 105: 168-173.
14. Horak F., Zieglmayer U.P.: Azelastine nasal spray for the treatment of allergic and nonalergic rhinitis. Expert Rev. Clin. Immunol. 2009, 5(6): 659-669.